Dark Mode Light Mode

Stock in Tylenol’s parent company rallies after Trump’s unproven claims

Tylenol’s parent company, Kenvue, saw its stock price rebound in premarket trading on Tuesday after U.S. President Donald Trump made unfounded claims about the drug.

Previous Post

Forward Industries wants to tokenize its Nasdaq shares on Solana

Next Post

U.S.-U.K. collaboration on crypto regulation - A game-changer for global markets

Advertisement
You have not selected any currencies to display